nodes	percent_of_prediction	percent_of_DWPC	metapath
Eletriptan—CYP2A6—Nevirapine—acquired immunodeficiency syndrome	0.0501	0.0726	CbGbCtD
Eletriptan—CYP2A6—Zidovudine—acquired immunodeficiency syndrome	0.0329	0.0477	CbGbCtD
Eletriptan—CYP2C19—Efavirenz—acquired immunodeficiency syndrome	0.0221	0.032	CbGbCtD
Eletriptan—CYP2C19—Lopinavir—acquired immunodeficiency syndrome	0.0207	0.03	CbGbCtD
Eletriptan—CYP2C19—Amprenavir—acquired immunodeficiency syndrome	0.0188	0.0272	CbGbCtD
Eletriptan—CYP2C19—Delavirdine—acquired immunodeficiency syndrome	0.0188	0.0272	CbGbCtD
Eletriptan—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0183	0.0266	CbGbCtD
Eletriptan—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0172	0.025	CbGbCtD
Eletriptan—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0172	0.025	CbGbCtD
Eletriptan—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0168	0.0243	CbGbCtD
Eletriptan—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0167	0.0242	CbGbCtD
Eletriptan—CYP2C19—Indinavir—acquired immunodeficiency syndrome	0.0162	0.0235	CbGbCtD
Eletriptan—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0158	0.0228	CbGbCtD
Eletriptan—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0158	0.0228	CbGbCtD
Eletriptan—CYP2C19—Nelfinavir—acquired immunodeficiency syndrome	0.0157	0.0228	CbGbCtD
Eletriptan—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0156	0.0226	CbGbCtD
Eletriptan—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0156	0.0226	CbGbCtD
Eletriptan—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0151	0.0219	CbGbCtD
Eletriptan—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0143	0.0207	CbGbCtD
Eletriptan—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0143	0.0207	CbGbCtD
Eletriptan—CYP2C19—Ritonavir—acquired immunodeficiency syndrome	0.0142	0.0206	CbGbCtD
Eletriptan—CYP2C19—Saquinavir—acquired immunodeficiency syndrome	0.0142	0.0206	CbGbCtD
Eletriptan—CYP2C19—Zidovudine—acquired immunodeficiency syndrome	0.0136	0.0197	CbGbCtD
Eletriptan—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0135	0.0195	CbGbCtD
Eletriptan—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0131	0.0189	CbGbCtD
Eletriptan—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0131	0.0189	CbGbCtD
Eletriptan—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0127	0.0184	CbGbCtD
Eletriptan—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0123	0.0178	CbGbCtD
Eletriptan—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0119	0.0173	CbGbCtD
Eletriptan—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0118	0.0171	CbGbCtD
Eletriptan—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0118	0.0171	CbGbCtD
Eletriptan—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0115	0.0166	CbGbCtD
Eletriptan—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0115	0.0166	CbGbCtD
Eletriptan—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0113	0.0164	CbGbCtD
Eletriptan—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.011	0.0159	CbGbCtD
Eletriptan—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0108	0.0157	CbGbCtD
Eletriptan—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0108	0.0157	CbGbCtD
Eletriptan—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0107	0.0154	CbGbCtD
Eletriptan—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.01	0.0145	CbGbCtD
Eletriptan—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.01	0.0145	CbGbCtD
Eletriptan—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00907	0.0131	CbGbCtD
Eletriptan—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00907	0.0131	CbGbCtD
Eletriptan—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0085	0.0123	CbGbCtD
Eletriptan—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00783	0.0113	CbGbCtD
Eletriptan—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0076	0.011	CbGbCtD
Eletriptan—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00687	0.00996	CbGbCtD
Eletriptan—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00687	0.00996	CbGbCtD
Eletriptan—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00659	0.00954	CbGbCtD
Eletriptan—HTR7—nerve—acquired immunodeficiency syndrome	0.00171	0.0413	CbGeAlD
Eletriptan—HTR7—endothelium—acquired immunodeficiency syndrome	0.00146	0.0352	CbGeAlD
Eletriptan—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00135	0.0327	CbGeAlD
Eletriptan—HTR7—blood plasma—acquired immunodeficiency syndrome	0.00129	0.0312	CbGeAlD
Eletriptan—CYP2C19—blood plasma—acquired immunodeficiency syndrome	0.00126	0.0305	CbGeAlD
Eletriptan—HTR1F—nervous system—acquired immunodeficiency syndrome	0.00122	0.0294	CbGeAlD
Eletriptan—HTR1F—central nervous system—acquired immunodeficiency syndrome	0.00117	0.0283	CbGeAlD
Eletriptan—HTR1E—nervous system—acquired immunodeficiency syndrome	0.00105	0.0255	CbGeAlD
Eletriptan—HTR1E—central nervous system—acquired immunodeficiency syndrome	0.00102	0.0245	CbGeAlD
Eletriptan—PTGS1—endothelium—acquired immunodeficiency syndrome	0.00101	0.0243	CbGeAlD
Eletriptan—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000979	0.0237	CbGeAlD
Eletriptan—HTR1F—brain—acquired immunodeficiency syndrome	0.000931	0.0225	CbGeAlD
Eletriptan—PTGS1—blood plasma—acquired immunodeficiency syndrome	0.000894	0.0216	CbGeAlD
Eletriptan—HTR1E—brain—acquired immunodeficiency syndrome	0.000806	0.0195	CbGeAlD
Eletriptan—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000747	0.018	CbGeAlD
Eletriptan—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000735	0.0177	CbGeAlD
Eletriptan—HTR2B—skin of body—acquired immunodeficiency syndrome	0.000726	0.0175	CbGeAlD
Eletriptan—CYP2A6—vagina—acquired immunodeficiency syndrome	0.000667	0.0161	CbGeAlD
Eletriptan—CYP2A6—lung—acquired immunodeficiency syndrome	0.000631	0.0152	CbGeAlD
Eletriptan—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.000592	0.0143	CbGeAlD
Eletriptan—HTR2B—digestive system—acquired immunodeficiency syndrome	0.000581	0.014	CbGeAlD
Eletriptan—HTR2B—blood—acquired immunodeficiency syndrome	0.000553	0.0134	CbGeAlD
Eletriptan—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000529	0.0128	CbGeAlD
Eletriptan—HTR2B—vagina—acquired immunodeficiency syndrome	0.000513	0.0124	CbGeAlD
Eletriptan—HTR1B—nervous system—acquired immunodeficiency syndrome	0.000499	0.012	CbGeAlD
Eletriptan—HTR7—digestive system—acquired immunodeficiency syndrome	0.000497	0.012	CbGeAlD
Eletriptan—CYP2C19—digestive system—acquired immunodeficiency syndrome	0.000486	0.0117	CbGeAlD
Eletriptan—HTR2B—lung—acquired immunodeficiency syndrome	0.000485	0.0117	CbGeAlD
Eletriptan—HTR1D—nervous system—acquired immunodeficiency syndrome	0.000483	0.0117	CbGeAlD
Eletriptan—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.00048	0.0116	CbGeAlD
Eletriptan—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.000478	0.0115	CbGeAlD
Eletriptan—HTR7—blood—acquired immunodeficiency syndrome	0.000474	0.0114	CbGeAlD
Eletriptan—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.000465	0.0112	CbGeAlD
Eletriptan—CYP2C19—blood—acquired immunodeficiency syndrome	0.000463	0.0112	CbGeAlD
Eletriptan—HTR7—spinal cord—acquired immunodeficiency syndrome	0.000457	0.011	CbGeAlD
Eletriptan—HTR2B—nervous system—acquired immunodeficiency syndrome	0.000449	0.0108	CbGeAlD
Eletriptan—CYP2A6—brain—acquired immunodeficiency syndrome	0.000446	0.0108	CbGeAlD
Eletriptan—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.000433	0.0104	CbGeAlD
Eletriptan—PTGS1—skin of body—acquired immunodeficiency syndrome	0.00043	0.0104	CbGeAlD
Eletriptan—CYP2C19—vagina—acquired immunodeficiency syndrome	0.000429	0.0104	CbGeAlD
Eletriptan—HTR7—lung—acquired immunodeficiency syndrome	0.000415	0.01	CbGeAlD
Eletriptan—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000403	0.00972	CbGeAlD
Eletriptan—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000388	0.00936	CbGeAlD
Eletriptan—HTR7—nervous system—acquired immunodeficiency syndrome	0.000385	0.00929	CbGeAlD
Eletriptan—HTR1B—brain—acquired immunodeficiency syndrome	0.000381	0.00921	CbGeAlD
Eletriptan—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000377	0.00909	CbGeAlD
Eletriptan—HTR7—central nervous system—acquired immunodeficiency syndrome	0.00037	0.00894	CbGeAlD
Eletriptan—HTR1D—brain—acquired immunodeficiency syndrome	0.000369	0.00891	CbGeAlD
Eletriptan—CYP2C9—blood—acquired immunodeficiency syndrome	0.000359	0.00866	CbGeAlD
Eletriptan—PTGS1—digestive system—acquired immunodeficiency syndrome	0.000344	0.0083	CbGeAlD
Eletriptan—HTR2B—brain—acquired immunodeficiency syndrome	0.000343	0.00829	CbGeAlD
Eletriptan—HTR2B—lymph node—acquired immunodeficiency syndrome	0.000332	0.00801	CbGeAlD
Eletriptan—PTGS1—blood—acquired immunodeficiency syndrome	0.000328	0.00791	CbGeAlD
Eletriptan—PTGS1—spinal cord—acquired immunodeficiency syndrome	0.000316	0.00762	CbGeAlD
Eletriptan—HTR1A—brain—acquired immunodeficiency syndrome	0.000308	0.00743	CbGeAlD
Eletriptan—PTGS1—vagina—acquired immunodeficiency syndrome	0.000304	0.00733	CbGeAlD
Eletriptan—HTR7—brain—acquired immunodeficiency syndrome	0.000294	0.0071	CbGeAlD
Eletriptan—ABCB1—retina—acquired immunodeficiency syndrome	0.000289	0.00699	CbGeAlD
Eletriptan—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000287	0.00694	CbGeAlD
Eletriptan—PTGS1—lung—acquired immunodeficiency syndrome	0.000287	0.00693	CbGeAlD
Eletriptan—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000283	0.00682	CbGeAlD
Eletriptan—CYP3A4—blood—acquired immunodeficiency syndrome	0.000274	0.00661	CbGeAlD
Eletriptan—CYP2D6—blood—acquired immunodeficiency syndrome	0.000269	0.0065	CbGeAlD
Eletriptan—PTGS1—nervous system—acquired immunodeficiency syndrome	0.000266	0.00642	CbGeAlD
Eletriptan—PTGS1—central nervous system—acquired immunodeficiency syndrome	0.000256	0.00618	CbGeAlD
Eletriptan—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000222	0.00536	CbGeAlD
Eletriptan—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000219	0.00528	CbGeAlD
Eletriptan—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000214	0.00516	CbGeAlD
Eletriptan—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.00021	0.00508	CbGeAlD
Eletriptan—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000206	0.00497	CbGeAlD
Eletriptan—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000203	0.00491	CbGeAlD
Eletriptan—PTGS1—brain—acquired immunodeficiency syndrome	0.000203	0.00491	CbGeAlD
Eletriptan—PTGS1—lymph node—acquired immunodeficiency syndrome	0.000196	0.00474	CbGeAlD
Eletriptan—ABCB1—blood—acquired immunodeficiency syndrome	0.000194	0.00468	CbGeAlD
Eletriptan—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000187	0.00453	CbGeAlD
Eletriptan—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000187	0.00451	CbGeAlD
Eletriptan—ABCB1—vagina—acquired immunodeficiency syndrome	0.00018	0.00434	CbGeAlD
Eletriptan—ABCB1—lung—acquired immunodeficiency syndrome	0.00017	0.0041	CbGeAlD
Eletriptan—CYP2D6—brain—acquired immunodeficiency syndrome	0.000167	0.00403	CbGeAlD
Eletriptan—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000157	0.0038	CbGeAlD
Eletriptan—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000151	0.00366	CbGeAlD
Eletriptan—ABCB1—brain—acquired immunodeficiency syndrome	0.00012	0.0029	CbGeAlD
Eletriptan—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000116	0.0028	CbGeAlD
Eletriptan—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.00011	0.000464	CcSEcCtD
Eletriptan—Ill-defined disorder—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.000464	CcSEcCtD
Eletriptan—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.000463	CcSEcCtD
Eletriptan—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.000463	CcSEcCtD
Eletriptan—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.00011	0.000462	CcSEcCtD
Eletriptan—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.000462	CcSEcCtD
Eletriptan—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.00011	0.000462	CcSEcCtD
Eletriptan—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.00046	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.00046	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000109	0.000459	CcSEcCtD
Eletriptan—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000109	0.000458	CcSEcCtD
Eletriptan—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000109	0.000458	CcSEcCtD
Eletriptan—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.000109	0.000458	CcSEcCtD
Eletriptan—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.000458	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000109	0.000457	CcSEcCtD
Eletriptan—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.000457	CcSEcCtD
Eletriptan—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000108	0.000457	CcSEcCtD
Eletriptan—Pain—Indinavir—acquired immunodeficiency syndrome	0.000108	0.000454	CcSEcCtD
Eletriptan—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000108	0.000454	CcSEcCtD
Eletriptan—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.000454	CcSEcCtD
Eletriptan—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000108	0.000454	CcSEcCtD
Eletriptan—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.000454	CcSEcCtD
Eletriptan—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000108	0.000453	CcSEcCtD
Eletriptan—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000452	CcSEcCtD
Eletriptan—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000107	0.000452	CcSEcCtD
Eletriptan—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000107	0.000452	CcSEcCtD
Eletriptan—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000107	0.000451	CcSEcCtD
Eletriptan—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000107	0.000451	CcSEcCtD
Eletriptan—Malaise—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.000451	CcSEcCtD
Eletriptan—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000107	0.00045	CcSEcCtD
Eletriptan—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000107	0.00045	CcSEcCtD
Eletriptan—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.000449	CcSEcCtD
Eletriptan—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.000449	CcSEcCtD
Eletriptan—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000106	0.000448	CcSEcCtD
Eletriptan—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000448	CcSEcCtD
Eletriptan—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.000448	CcSEcCtD
Eletriptan—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000106	0.000447	CcSEcCtD
Eletriptan—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.000446	CcSEcCtD
Eletriptan—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000446	CcSEcCtD
Eletriptan—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000446	CcSEcCtD
Eletriptan—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000444	CcSEcCtD
Eletriptan—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.000444	CcSEcCtD
Eletriptan—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000105	0.000443	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000443	CcSEcCtD
Eletriptan—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000105	0.000442	CcSEcCtD
Eletriptan—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000441	CcSEcCtD
Eletriptan—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000439	CcSEcCtD
Eletriptan—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000104	0.000438	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000104	0.000438	CcSEcCtD
Eletriptan—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000104	0.000437	CcSEcCtD
Eletriptan—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000104	0.000436	CcSEcCtD
Eletriptan—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000104	0.000436	CcSEcCtD
Eletriptan—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.000436	CcSEcCtD
Eletriptan—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000104	0.000436	CcSEcCtD
Eletriptan—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000103	0.000436	CcSEcCtD
Eletriptan—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000103	0.000435	CcSEcCtD
Eletriptan—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000103	0.000434	CcSEcCtD
Eletriptan—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.000434	CcSEcCtD
Eletriptan—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000103	0.000434	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000433	CcSEcCtD
Eletriptan—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000433	CcSEcCtD
Eletriptan—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000103	0.000433	CcSEcCtD
Eletriptan—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.000433	CcSEcCtD
Eletriptan—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000102	0.000431	CcSEcCtD
Eletriptan—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000431	CcSEcCtD
Eletriptan—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000431	CcSEcCtD
Eletriptan—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000102	0.000429	CcSEcCtD
Eletriptan—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000102	0.000429	CcSEcCtD
Eletriptan—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000102	0.000429	CcSEcCtD
Eletriptan—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000102	0.000429	CcSEcCtD
Eletriptan—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000102	0.000429	CcSEcCtD
Eletriptan—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000102	0.000428	CcSEcCtD
Eletriptan—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000102	0.000428	CcSEcCtD
Eletriptan—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.000428	CcSEcCtD
Eletriptan—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000101	0.000427	CcSEcCtD
Eletriptan—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000101	0.000426	CcSEcCtD
Eletriptan—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000425	CcSEcCtD
Eletriptan—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000425	CcSEcCtD
Eletriptan—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000101	0.000424	CcSEcCtD
Eletriptan—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000101	0.000423	CcSEcCtD
Eletriptan—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.0001	0.000423	CcSEcCtD
Eletriptan—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.0001	0.000423	CcSEcCtD
Eletriptan—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.0001	0.000422	CcSEcCtD
Eletriptan—Shock—Saquinavir—acquired immunodeficiency syndrome	9.98e-05	0.000421	CcSEcCtD
Eletriptan—Discomfort—Lamivudine—acquired immunodeficiency syndrome	9.98e-05	0.00042	CcSEcCtD
Eletriptan—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	9.97e-05	0.00042	CcSEcCtD
Eletriptan—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	9.97e-05	0.00042	CcSEcCtD
Eletriptan—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	9.95e-05	0.000419	CcSEcCtD
Eletriptan—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	9.95e-05	0.000419	CcSEcCtD
Eletriptan—Vomiting—Stavudine—acquired immunodeficiency syndrome	9.92e-05	0.000418	CcSEcCtD
Eletriptan—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	9.91e-05	0.000418	CcSEcCtD
Eletriptan—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	9.88e-05	0.000416	CcSEcCtD
Eletriptan—Rash—Nelfinavir—acquired immunodeficiency syndrome	9.87e-05	0.000416	CcSEcCtD
Eletriptan—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	9.86e-05	0.000415	CcSEcCtD
Eletriptan—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	9.86e-05	0.000415	CcSEcCtD
Eletriptan—Hypotension—Ritonavir—acquired immunodeficiency syndrome	9.85e-05	0.000415	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	9.84e-05	0.000415	CcSEcCtD
Eletriptan—Rash—Stavudine—acquired immunodeficiency syndrome	9.84e-05	0.000414	CcSEcCtD
Eletriptan—Fatigue—Delavirdine—acquired immunodeficiency syndrome	9.83e-05	0.000414	CcSEcCtD
Eletriptan—Dermatitis—Stavudine—acquired immunodeficiency syndrome	9.83e-05	0.000414	CcSEcCtD
Eletriptan—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	9.82e-05	0.000414	CcSEcCtD
Eletriptan—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	9.81e-05	0.000413	CcSEcCtD
Eletriptan—Headache—Nelfinavir—acquired immunodeficiency syndrome	9.81e-05	0.000413	CcSEcCtD
Eletriptan—Headache—Stavudine—acquired immunodeficiency syndrome	9.78e-05	0.000412	CcSEcCtD
Eletriptan—Vomiting—Abacavir—acquired immunodeficiency syndrome	9.77e-05	0.000412	CcSEcCtD
Eletriptan—Confusional state—Lamivudine—acquired immunodeficiency syndrome	9.76e-05	0.000411	CcSEcCtD
Eletriptan—Constipation—Delavirdine—acquired immunodeficiency syndrome	9.75e-05	0.000411	CcSEcCtD
Eletriptan—Pain—Delavirdine—acquired immunodeficiency syndrome	9.75e-05	0.000411	CcSEcCtD
Eletriptan—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	9.75e-05	0.000411	CcSEcCtD
Eletriptan—Asthenia—Zidovudine—acquired immunodeficiency syndrome	9.73e-05	0.00041	CcSEcCtD
Eletriptan—Rash—Abacavir—acquired immunodeficiency syndrome	9.69e-05	0.000408	CcSEcCtD
Eletriptan—Dermatitis—Abacavir—acquired immunodeficiency syndrome	9.68e-05	0.000408	CcSEcCtD
Eletriptan—Oedema—Lamivudine—acquired immunodeficiency syndrome	9.68e-05	0.000408	CcSEcCtD
Eletriptan—Anorexia—Saquinavir—acquired immunodeficiency syndrome	9.67e-05	0.000408	CcSEcCtD
Eletriptan—Headache—Abacavir—acquired immunodeficiency syndrome	9.63e-05	0.000406	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	9.61e-05	0.000405	CcSEcCtD
Eletriptan—Nausea—Nevirapine—acquired immunodeficiency syndrome	9.6e-05	0.000404	CcSEcCtD
Eletriptan—Pruritus—Zidovudine—acquired immunodeficiency syndrome	9.6e-05	0.000404	CcSEcCtD
Eletriptan—Insomnia—Ritonavir—acquired immunodeficiency syndrome	9.54e-05	0.000402	CcSEcCtD
Eletriptan—Shock—Lamivudine—acquired immunodeficiency syndrome	9.53e-05	0.000401	CcSEcCtD
Eletriptan—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	9.49e-05	0.0004	CcSEcCtD
Eletriptan—Hypotension—Saquinavir—acquired immunodeficiency syndrome	9.48e-05	0.000399	CcSEcCtD
Eletriptan—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	9.47e-05	0.000399	CcSEcCtD
Eletriptan—Urticaria—Efavirenz—acquired immunodeficiency syndrome	9.47e-05	0.000399	CcSEcCtD
Eletriptan—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	9.42e-05	0.000397	CcSEcCtD
Eletriptan—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	9.42e-05	0.000397	CcSEcCtD
Eletriptan—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	9.4e-05	0.000396	CcSEcCtD
Eletriptan—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	9.4e-05	0.000396	CcSEcCtD
Eletriptan—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	9.4e-05	0.000396	CcSEcCtD
Eletriptan—Somnolence—Ritonavir—acquired immunodeficiency syndrome	9.37e-05	0.000395	CcSEcCtD
Eletriptan—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	9.36e-05	0.000394	CcSEcCtD
Eletriptan—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	9.32e-05	0.000393	CcSEcCtD
Eletriptan—Nausea—Nelfinavir—acquired immunodeficiency syndrome	9.3e-05	0.000392	CcSEcCtD
Eletriptan—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	9.29e-05	0.000391	CcSEcCtD
Eletriptan—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	9.28e-05	0.000391	CcSEcCtD
Eletriptan—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	9.28e-05	0.000391	CcSEcCtD
Eletriptan—Nausea—Stavudine—acquired immunodeficiency syndrome	9.27e-05	0.00039	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	9.25e-05	0.00039	CcSEcCtD
Eletriptan—Anorexia—Lamivudine—acquired immunodeficiency syndrome	9.23e-05	0.000389	CcSEcCtD
Eletriptan—Insomnia—Saquinavir—acquired immunodeficiency syndrome	9.18e-05	0.000387	CcSEcCtD
Eletriptan—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	9.17e-05	0.000386	CcSEcCtD
Eletriptan—Nausea—Abacavir—acquired immunodeficiency syndrome	9.13e-05	0.000385	CcSEcCtD
Eletriptan—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	9.11e-05	0.000384	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	9.1e-05	0.000383	CcSEcCtD
Eletriptan—Fatigue—Ritonavir—acquired immunodeficiency syndrome	9.09e-05	0.000383	CcSEcCtD
Eletriptan—Urticaria—Delavirdine—acquired immunodeficiency syndrome	9.06e-05	0.000382	CcSEcCtD
Eletriptan—Asthenia—Indinavir—acquired immunodeficiency syndrome	9.05e-05	0.000381	CcSEcCtD
Eletriptan—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	9.05e-05	0.000381	CcSEcCtD
Eletriptan—Hypotension—Lamivudine—acquired immunodeficiency syndrome	9.05e-05	0.000381	CcSEcCtD
Eletriptan—Somnolence—Saquinavir—acquired immunodeficiency syndrome	9.02e-05	0.00038	CcSEcCtD
Eletriptan—Pain—Ritonavir—acquired immunodeficiency syndrome	9.02e-05	0.00038	CcSEcCtD
Eletriptan—Constipation—Ritonavir—acquired immunodeficiency syndrome	9.02e-05	0.00038	CcSEcCtD
Eletriptan—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	9.01e-05	0.00038	CcSEcCtD
Eletriptan—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	9.01e-05	0.00038	CcSEcCtD
Eletriptan—Dizziness—Zidovudine—acquired immunodeficiency syndrome	8.97e-05	0.000378	CcSEcCtD
Eletriptan—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	8.93e-05	0.000376	CcSEcCtD
Eletriptan—Pruritus—Indinavir—acquired immunodeficiency syndrome	8.92e-05	0.000376	CcSEcCtD
Eletriptan—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	8.82e-05	0.000372	CcSEcCtD
Eletriptan—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	8.82e-05	0.000372	CcSEcCtD
Eletriptan—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	8.78e-05	0.00037	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.000369	CcSEcCtD
Eletriptan—Insomnia—Lamivudine—acquired immunodeficiency syndrome	8.76e-05	0.000369	CcSEcCtD
Eletriptan—Fatigue—Saquinavir—acquired immunodeficiency syndrome	8.75e-05	0.000369	CcSEcCtD
Eletriptan—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	8.69e-05	0.000366	CcSEcCtD
Eletriptan—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	8.69e-05	0.000366	CcSEcCtD
Eletriptan—Constipation—Saquinavir—acquired immunodeficiency syndrome	8.68e-05	0.000366	CcSEcCtD
Eletriptan—Pain—Saquinavir—acquired immunodeficiency syndrome	8.68e-05	0.000366	CcSEcCtD
Eletriptan—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	8.63e-05	0.000364	CcSEcCtD
Eletriptan—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	8.63e-05	0.000364	CcSEcCtD
Eletriptan—Vomiting—Zidovudine—acquired immunodeficiency syndrome	8.62e-05	0.000363	CcSEcCtD
Eletriptan—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	8.62e-05	0.000363	CcSEcCtD
Eletriptan—Somnolence—Lamivudine—acquired immunodeficiency syndrome	8.61e-05	0.000363	CcSEcCtD
Eletriptan—Rash—Zidovudine—acquired immunodeficiency syndrome	8.55e-05	0.00036	CcSEcCtD
Eletriptan—Asthenia—Efavirenz—acquired immunodeficiency syndrome	8.55e-05	0.00036	CcSEcCtD
Eletriptan—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	8.54e-05	0.00036	CcSEcCtD
Eletriptan—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	8.52e-05	0.000359	CcSEcCtD
Eletriptan—Headache—Zidovudine—acquired immunodeficiency syndrome	8.5e-05	0.000358	CcSEcCtD
Eletriptan—Pruritus—Efavirenz—acquired immunodeficiency syndrome	8.43e-05	0.000355	CcSEcCtD
Eletriptan—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	8.42e-05	0.000355	CcSEcCtD
Eletriptan—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	8.4e-05	0.000354	CcSEcCtD
Eletriptan—Urticaria—Ritonavir—acquired immunodeficiency syndrome	8.38e-05	0.000353	CcSEcCtD
Eletriptan—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	8.36e-05	0.000352	CcSEcCtD
Eletriptan—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	8.36e-05	0.000352	CcSEcCtD
Eletriptan—Fatigue—Lamivudine—acquired immunodeficiency syndrome	8.35e-05	0.000352	CcSEcCtD
Eletriptan—Dizziness—Indinavir—acquired immunodeficiency syndrome	8.34e-05	0.000351	CcSEcCtD
Eletriptan—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	8.34e-05	0.000351	CcSEcCtD
Eletriptan—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	8.34e-05	0.000351	CcSEcCtD
Eletriptan—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	8.3e-05	0.00035	CcSEcCtD
Eletriptan—Pain—Lamivudine—acquired immunodeficiency syndrome	8.28e-05	0.000349	CcSEcCtD
Eletriptan—Constipation—Lamivudine—acquired immunodeficiency syndrome	8.28e-05	0.000349	CcSEcCtD
Eletriptan—Asthenia—Delavirdine—acquired immunodeficiency syndrome	8.18e-05	0.000345	CcSEcCtD
Eletriptan—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	8.15e-05	0.000343	CcSEcCtD
Eletriptan—Pruritus—Delavirdine—acquired immunodeficiency syndrome	8.07e-05	0.00034	CcSEcCtD
Eletriptan—Urticaria—Saquinavir—acquired immunodeficiency syndrome	8.06e-05	0.00034	CcSEcCtD
Eletriptan—Nausea—Zidovudine—acquired immunodeficiency syndrome	8.06e-05	0.000339	CcSEcCtD
Eletriptan—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	8.02e-05	0.000338	CcSEcCtD
Eletriptan—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	8.02e-05	0.000338	CcSEcCtD
Eletriptan—Vomiting—Indinavir—acquired immunodeficiency syndrome	8.02e-05	0.000338	CcSEcCtD
Eletriptan—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	7.98e-05	0.000336	CcSEcCtD
Eletriptan—Rash—Indinavir—acquired immunodeficiency syndrome	7.95e-05	0.000335	CcSEcCtD
Eletriptan—Dermatitis—Indinavir—acquired immunodeficiency syndrome	7.95e-05	0.000335	CcSEcCtD
Eletriptan—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	7.92e-05	0.000334	CcSEcCtD
Eletriptan—Headache—Indinavir—acquired immunodeficiency syndrome	7.9e-05	0.000333	CcSEcCtD
Eletriptan—Dizziness—Efavirenz—acquired immunodeficiency syndrome	7.88e-05	0.000332	CcSEcCtD
Eletriptan—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	7.8e-05	0.000329	CcSEcCtD
Eletriptan—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	7.77e-05	0.000327	CcSEcCtD
Eletriptan—Urticaria—Lamivudine—acquired immunodeficiency syndrome	7.69e-05	0.000324	CcSEcCtD
Eletriptan—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	7.65e-05	0.000322	CcSEcCtD
Eletriptan—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	7.65e-05	0.000322	CcSEcCtD
Eletriptan—Vomiting—Efavirenz—acquired immunodeficiency syndrome	7.58e-05	0.000319	CcSEcCtD
Eletriptan—Asthenia—Ritonavir—acquired immunodeficiency syndrome	7.57e-05	0.000319	CcSEcCtD
Eletriptan—Dizziness—Delavirdine—acquired immunodeficiency syndrome	7.54e-05	0.000318	CcSEcCtD
Eletriptan—Rash—Efavirenz—acquired immunodeficiency syndrome	7.51e-05	0.000317	CcSEcCtD
Eletriptan—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	7.51e-05	0.000316	CcSEcCtD
Eletriptan—Nausea—Indinavir—acquired immunodeficiency syndrome	7.49e-05	0.000316	CcSEcCtD
Eletriptan—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	7.48e-05	0.000315	CcSEcCtD
Eletriptan—Headache—Efavirenz—acquired immunodeficiency syndrome	7.47e-05	0.000314	CcSEcCtD
Eletriptan—Pruritus—Ritonavir—acquired immunodeficiency syndrome	7.46e-05	0.000314	CcSEcCtD
Eletriptan—Asthenia—Saquinavir—acquired immunodeficiency syndrome	7.28e-05	0.000307	CcSEcCtD
Eletriptan—Vomiting—Delavirdine—acquired immunodeficiency syndrome	7.25e-05	0.000305	CcSEcCtD
Eletriptan—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	7.21e-05	0.000304	CcSEcCtD
Eletriptan—Rash—Delavirdine—acquired immunodeficiency syndrome	7.19e-05	0.000303	CcSEcCtD
Eletriptan—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	7.18e-05	0.000303	CcSEcCtD
Eletriptan—Pruritus—Saquinavir—acquired immunodeficiency syndrome	7.18e-05	0.000302	CcSEcCtD
Eletriptan—Headache—Delavirdine—acquired immunodeficiency syndrome	7.14e-05	0.000301	CcSEcCtD
Eletriptan—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	7.13e-05	0.0003	CcSEcCtD
Eletriptan—Nausea—Efavirenz—acquired immunodeficiency syndrome	7.08e-05	0.000298	CcSEcCtD
Eletriptan—Dizziness—Ritonavir—acquired immunodeficiency syndrome	6.97e-05	0.000294	CcSEcCtD
Eletriptan—Asthenia—Lamivudine—acquired immunodeficiency syndrome	6.95e-05	0.000293	CcSEcCtD
Eletriptan—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	6.94e-05	0.000293	CcSEcCtD
Eletriptan—Pruritus—Lamivudine—acquired immunodeficiency syndrome	6.85e-05	0.000289	CcSEcCtD
Eletriptan—Nausea—Delavirdine—acquired immunodeficiency syndrome	6.77e-05	0.000285	CcSEcCtD
Eletriptan—Dizziness—Saquinavir—acquired immunodeficiency syndrome	6.71e-05	0.000283	CcSEcCtD
Eletriptan—Vomiting—Ritonavir—acquired immunodeficiency syndrome	6.7e-05	0.000282	CcSEcCtD
Eletriptan—Rash—Ritonavir—acquired immunodeficiency syndrome	6.65e-05	0.00028	CcSEcCtD
Eletriptan—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	6.64e-05	0.00028	CcSEcCtD
Eletriptan—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	6.62e-05	0.000279	CcSEcCtD
Eletriptan—Headache—Ritonavir—acquired immunodeficiency syndrome	6.61e-05	0.000278	CcSEcCtD
Eletriptan—Vomiting—Saquinavir—acquired immunodeficiency syndrome	6.45e-05	0.000272	CcSEcCtD
Eletriptan—Dizziness—Lamivudine—acquired immunodeficiency syndrome	6.4e-05	0.00027	CcSEcCtD
Eletriptan—Rash—Saquinavir—acquired immunodeficiency syndrome	6.4e-05	0.00027	CcSEcCtD
Eletriptan—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	6.39e-05	0.000269	CcSEcCtD
Eletriptan—Headache—Saquinavir—acquired immunodeficiency syndrome	6.36e-05	0.000268	CcSEcCtD
Eletriptan—Nausea—Ritonavir—acquired immunodeficiency syndrome	6.26e-05	0.000264	CcSEcCtD
Eletriptan—Vomiting—Lamivudine—acquired immunodeficiency syndrome	6.16e-05	0.000259	CcSEcCtD
Eletriptan—Rash—Lamivudine—acquired immunodeficiency syndrome	6.1e-05	0.000257	CcSEcCtD
Eletriptan—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	6.1e-05	0.000257	CcSEcCtD
Eletriptan—Headache—Lamivudine—acquired immunodeficiency syndrome	6.07e-05	0.000256	CcSEcCtD
Eletriptan—Nausea—Saquinavir—acquired immunodeficiency syndrome	6.03e-05	0.000254	CcSEcCtD
Eletriptan—Nausea—Lamivudine—acquired immunodeficiency syndrome	5.75e-05	0.000242	CcSEcCtD
Eletriptan—HTR1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	5.71e-05	0.00184	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	5.7e-05	0.00183	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.63e-05	0.00181	CbGpPWpGaD
Eletriptan—HTR1F—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.56e-05	0.00179	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.54e-05	0.00178	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.54e-05	0.00178	CbGpPWpGaD
Eletriptan—HTR1A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	5.5e-05	0.00177	CbGpPWpGaD
Eletriptan—HTR1E—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.43e-05	0.00174	CbGpPWpGaD
Eletriptan—HTR1E—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.43e-05	0.00174	CbGpPWpGaD
Eletriptan—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.39e-05	0.00173	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.31e-05	0.00171	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.29e-05	0.0017	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.24e-05	0.00168	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.24e-05	0.00168	CbGpPWpGaD
Eletriptan—HTR1F—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.22e-05	0.00168	CbGpPWpGaD
Eletriptan—HTR1F—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.22e-05	0.00168	CbGpPWpGaD
Eletriptan—HTR1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	5.16e-05	0.00166	CbGpPWpGaD
Eletriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	5.1e-05	0.00164	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.01e-05	0.00161	CbGpPWpGaD
Eletriptan—HTR7—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.99e-05	0.0016	CbGpPWpGaD
Eletriptan—HTR1D—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.95e-05	0.00159	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.93e-05	0.00158	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.93e-05	0.00158	CbGpPWpGaD
Eletriptan—PTGS1—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	4.9e-05	0.00158	CbGpPWpGaD
Eletriptan—HTR1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	4.86e-05	0.00156	CbGpPWpGaD
Eletriptan—HTR1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	4.86e-05	0.00156	CbGpPWpGaD
Eletriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	4.85e-05	0.00156	CbGpPWpGaD
Eletriptan—HTR1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.85e-05	0.00156	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	4.78e-05	0.00154	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—TAT—acquired immunodeficiency syndrome	4.76e-05	0.00153	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	4.74e-05	0.00152	CbGpPWpGaD
Eletriptan—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	4.65e-05	0.00149	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.63e-05	0.00149	CbGpPWpGaD
Eletriptan—HTR2B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.56e-05	0.00146	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—TAT—acquired immunodeficiency syndrome	4.5e-05	0.00145	CbGpPWpGaD
Eletriptan—HTR7—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.49e-05	0.00144	CbGpPWpGaD
Eletriptan—HTR1D—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.46e-05	0.00143	CbGpPWpGaD
Eletriptan—HTR1F—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.38e-05	0.00141	CbGpPWpGaD
Eletriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	4.37e-05	0.0014	CbGpPWpGaD
Eletriptan—HTR1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.37e-05	0.0014	CbGpPWpGaD
Eletriptan—HTR1F—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.31e-05	0.00139	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	4.29e-05	0.00138	CbGpPWpGaD
Eletriptan—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	4.13e-05	0.00133	CbGpPWpGaD
Eletriptan—HTR1E—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.13e-05	0.00133	CbGpPWpGaD
Eletriptan—HTR2B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.1e-05	0.00132	CbGpPWpGaD
Eletriptan—HTR1E—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.07e-05	0.00131	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—AGPS—acquired immunodeficiency syndrome	4.05e-05	0.0013	CbGpPWpGaD
Eletriptan—HTR1F—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.97e-05	0.00128	CbGpPWpGaD
Eletriptan—PTGS1—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	3.96e-05	0.00127	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.96e-05	0.00127	CbGpPWpGaD
Eletriptan—HTR1F—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.94e-05	0.00127	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.94e-05	0.00127	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.93e-05	0.00126	CbGpPWpGaD
Eletriptan—HTR1F—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.92e-05	0.00126	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.91e-05	0.00126	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.85e-05	0.00124	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.83e-05	0.00123	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—AGPS—acquired immunodeficiency syndrome	3.83e-05	0.00123	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.78e-05	0.00122	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.78e-05	0.00122	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.76e-05	0.00121	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.76e-05	0.00121	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.75e-05	0.00121	CbGpPWpGaD
Eletriptan—HTR1E—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.72e-05	0.0012	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.7e-05	0.00119	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.7e-05	0.00119	CbGpPWpGaD
Eletriptan—HTR1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	3.69e-05	0.00119	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.69e-05	0.00119	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.68e-05	0.00118	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.68e-05	0.00118	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.68e-05	0.00118	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.68e-05	0.00118	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.63e-05	0.00117	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.61e-05	0.00116	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.6e-05	0.00116	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.6e-05	0.00116	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.6e-05	0.00116	CbGpPWpGaD
Eletriptan—HTR1F—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.58e-05	0.00115	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.58e-05	0.00115	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.55e-05	0.00114	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.48e-05	0.00112	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.46e-05	0.00111	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.46e-05	0.00111	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.42e-05	0.0011	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.42e-05	0.0011	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.4e-05	0.00109	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.38e-05	0.00109	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.38e-05	0.00109	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.38e-05	0.00109	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.36e-05	0.00108	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.36e-05	0.00108	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.34e-05	0.00107	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.34e-05	0.00107	CbGpPWpGaD
Eletriptan—HTR1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	3.33e-05	0.00107	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.33e-05	0.00107	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.28e-05	0.00106	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.27e-05	0.00105	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.27e-05	0.00105	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.27e-05	0.00105	CbGpPWpGaD
Eletriptan—HTR1A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	3.21e-05	0.00103	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.13e-05	0.001	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.1e-05	0.000995	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.09e-05	0.000992	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.09e-05	0.000992	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.07e-05	0.000988	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.07e-05	0.000988	CbGpPWpGaD
Eletriptan—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	3.01e-05	0.000967	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.93e-05	0.000942	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.92e-05	0.000938	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.91e-05	0.000936	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.91e-05	0.000936	CbGpPWpGaD
Eletriptan—HTR7—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	2.85e-05	0.000918	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.82e-05	0.000906	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.8e-05	0.000901	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.8e-05	0.000901	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.8e-05	0.0009	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.78e-05	0.000892	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.76e-05	0.000886	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—TAT—acquired immunodeficiency syndrome	2.75e-05	0.000882	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	2.74e-05	0.000882	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	2.74e-05	0.000882	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.74e-05	0.000881	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.7e-05	0.000868	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	2.68e-05	0.000861	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.65e-05	0.000852	CbGpPWpGaD
Eletriptan—HTR1A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	2.59e-05	0.000833	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.57e-05	0.000828	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.56e-05	0.000822	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.54e-05	0.000817	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.54e-05	0.000816	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.54e-05	0.000815	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.53e-05	0.000815	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	2.53e-05	0.000812	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.52e-05	0.000811	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.52e-05	0.00081	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.5e-05	0.000805	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	2.5e-05	0.000805	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.49e-05	0.000801	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.49e-05	0.000801	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.49e-05	0.0008	CbGpPWpGaD
Eletriptan—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.47e-05	0.000795	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.47e-05	0.000794	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.45e-05	0.000788	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.35e-05	0.000755	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.34e-05	0.000751	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.34e-05	0.000751	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—AGPS—acquired immunodeficiency syndrome	2.33e-05	0.00075	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.32e-05	0.000746	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.32e-05	0.000746	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.31e-05	0.000743	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.3e-05	0.000741	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.3e-05	0.00074	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.29e-05	0.000736	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.28e-05	0.000732	CbGpPWpGaD
Eletriptan—HTR1F—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.28e-05	0.000732	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.27e-05	0.000731	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.24e-05	0.000721	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.21e-05	0.000712	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.18e-05	0.000701	CbGpPWpGaD
Eletriptan—HTR1E—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.15e-05	0.000691	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	2.15e-05	0.00069	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.13e-05	0.000686	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	2.13e-05	0.000684	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.12e-05	0.00068	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.11e-05	0.000679	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.11e-05	0.000677	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.1e-05	0.000675	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.09e-05	0.000671	CbGpPWpGaD
Eletriptan—HTR1F—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.07e-05	0.000665	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.06e-05	0.000661	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.06e-05	0.000661	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2e-05	0.000641	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.99e-05	0.000639	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.99e-05	0.000639	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.97e-05	0.000634	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.97e-05	0.000634	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.95e-05	0.000627	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.93e-05	0.000621	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.93e-05	0.000621	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.93e-05	0.000621	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.9e-05	0.000609	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.88e-05	0.000605	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.87e-05	0.0006	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.86e-05	0.000599	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.82e-05	0.000584	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.82e-05	0.000584	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.73e-05	0.000557	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.71e-05	0.000549	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.65e-05	0.000531	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.57e-05	0.000503	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.51e-05	0.000486	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.5e-05	0.000483	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.49e-05	0.000479	CbGpPWpGaD
Eletriptan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.48e-05	0.000477	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.48e-05	0.000475	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.47e-05	0.000473	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.47e-05	0.000473	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.47e-05	0.000473	CbGpPWpGaD
Eletriptan—HTR7—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.47e-05	0.000471	CbGpPWpGaD
Eletriptan—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.46e-05	0.000468	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.45e-05	0.000465	CbGpPWpGaD
Eletriptan—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.43e-05	0.000459	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.4e-05	0.000451	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.38e-05	0.000444	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.36e-05	0.000438	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.36e-05	0.000437	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.35e-05	0.000435	CbGpPWpGaD
Eletriptan—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.34e-05	0.000431	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.33e-05	0.000428	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.32e-05	0.000426	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.32e-05	0.000425	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.3e-05	0.000416	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.24e-05	0.0004	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.22e-05	0.000393	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.22e-05	0.000391	CbGpPWpGaD
Eletriptan—HTR1F—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.22e-05	0.000391	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.15e-05	0.000371	CbGpPWpGaD
Eletriptan—HTR1E—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.15e-05	0.000369	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.12e-05	0.00036	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.1e-05	0.000355	CbGpPWpGaD
Eletriptan—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.09e-05	0.000349	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.08e-05	0.000346	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.01e-05	0.000324	CbGpPWpGaD
Eletriptan—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.98e-06	0.000321	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.87e-06	0.000317	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	9.8e-06	0.000315	CbGpPWpGaD
Eletriptan—PTGS1—Metabolism—ALB—acquired immunodeficiency syndrome	8.3e-06	0.000267	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.87e-06	0.000253	CbGpPWpGaD
Eletriptan—CYP2A6—Metabolism—ALB—acquired immunodeficiency syndrome	7.85e-06	0.000252	CbGpPWpGaD
Eletriptan—HTR7—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.83e-06	0.000252	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.82e-06	0.000251	CbGpPWpGaD
Eletriptan—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.78e-06	0.00025	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.65e-06	0.000246	CbGpPWpGaD
Eletriptan—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.61e-06	0.000245	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.19e-06	0.000231	CbGpPWpGaD
Eletriptan—HTR1F—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.18e-06	0.000231	CbGpPWpGaD
Eletriptan—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.15e-06	0.00023	CbGpPWpGaD
Eletriptan—HTR1E—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.78e-06	0.000218	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.83e-06	0.000187	CbGpPWpGaD
Eletriptan—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.8e-06	0.000186	CbGpPWpGaD
Eletriptan—CYP2C19—Metabolism—ALB—acquired immunodeficiency syndrome	4.79e-06	0.000154	CbGpPWpGaD
Eletriptan—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	4.67e-06	0.00015	CbGpPWpGaD
Eletriptan—HTR7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.62e-06	0.000149	CbGpPWpGaD
Eletriptan—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.59e-06	0.000148	CbGpPWpGaD
Eletriptan—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.5e-06	0.000145	CbGpPWpGaD
Eletriptan—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	4.4e-06	0.000142	CbGpPWpGaD
Eletriptan—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	4.37e-06	0.00014	CbGpPWpGaD
Eletriptan—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.23e-06	0.000136	CbGpPWpGaD
Eletriptan—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.43e-06	0.00011	CbGpPWpGaD
Eletriptan—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.88e-06	9.25e-05	CbGpPWpGaD
